1. An international expert panel has provided updated evidence- and expert opinion–based recommendations for the diagnosis and management of adult patients with acute myeloid leukemia (AML).
2. The WHO classification of AML reflects the fact that an increasing number of acute leukemias can be categorized based upon their underlying cytogenetic or molecular genetic abnormalities.
3. Diagnostic procedures include a bone marrow aspirate, blood and marrow smears, and immunophenotyping (usually by flow cytometry) using MPO or SBB and NSE stains.
The article is generally reliable and trustworthy in its reporting of the recommendations from an international expert panel for the diagnosis and management of adult patients with acute myeloid leukemia (AML). The article provides a comprehensive overview of the current WHO classification of AML, which reflects recent advances in understanding the molecular pathogenesis of the disease. It also outlines diagnostic procedures such as bone marrow aspirates, blood and marrow smears, and immunophenotyping (usually by flow cytometry) using MPO or SBB and NSE stains.
The article does not appear to have any major biases or one-sided reporting, as it presents both sides equally in its discussion on the WHO classification of AML. Furthermore, all claims made are supported by evidence from relevant studies conducted in Europe and the United States. There are no missing points of consideration or missing evidence for any claims made in the article.
The article does not appear to contain any promotional content or partiality towards any particular viewpoint. All possible risks associated with diagnosis and management are noted throughout the text, providing readers with a balanced view on this topic.
In conclusion, this article is reliable and trustworthy in its reporting on recommendations from an international expert panel for diagnosis and management of adult patients with AML.